Hangzhou Tigermed Consulting Co., Ltd.
HNGZY · OTC
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.16 | 0.91 | -0.27 | 0.07 |
| FCF Yield | 1.63% | 0.63% | 0.59% | 1.75% |
| EV / EBITDA | 31.22 | 82.66 | 142.10 | -89.29 |
| Quality | ||||
| ROIC | 0.59% | 0.95% | 0.41% | -1.68% |
| Gross Margin | 27.47% | 30.14% | 30.03% | 17.70% |
| Cash Conversion Ratio | 0.74 | – | 1.20 | – |
| Growth | ||||
| Revenue 3-Year CAGR | -11.77% | -3.38% | -2.77% | -2.39% |
| Free Cash Flow Growth | -64.49% | 5.41% | -65.93% | 35.04% |
| Safety | ||||
| Net Debt / EBITDA | 0.13 | 2.09 | 7.20 | -2.01 |
| Interest Coverage | 13.05 | 17.92 | 4.55 | -17.02 |
| Efficiency | ||||
| Inventory Turnover | 29.15 | 27.00 | 30.01 | 39.55 |
| Cash Conversion Cycle | 203.82 | 201.35 | 210.05 | 216.03 |